Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Down 18.2% in April

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 786,000 shares, a decline of 18.2% from the March 31st total of 960,700 shares. Based on an average daily trading volume, of 111,000 shares, the short-interest ratio is presently 7.1 days. Currently, 3.4% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in shares of Sera Prognostics by 7,357.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company's stock worth $6,902,000 after buying an additional 873,002 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Sera Prognostics during the fourth quarter worth about $1,285,000. Millennium Management LLC bought a new position in shares of Sera Prognostics in the fourth quarter worth about $576,000. AWM Investment Company Inc. boosted its stake in shares of Sera Prognostics by 12.2% in the 4th quarter. AWM Investment Company Inc. now owns 585,134 shares of the company's stock valued at $4,763,000 after purchasing an additional 63,820 shares in the last quarter. Finally, Sanders Morris Harris LLC grew its holdings in shares of Sera Prognostics by 165.7% during the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company's stock valued at $725,000 after purchasing an additional 56,500 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Price Performance

Sera Prognostics stock traded down $0.11 during mid-day trading on Monday, reaching $2.80. 110,274 shares of the company were exchanged, compared to its average volume of 131,327. The firm has a market cap of $105.46 million, a PE ratio of -2.83 and a beta of 0.99. The company has a fifty day simple moving average of $3.62 and a 200-day simple moving average of $5.63. Sera Prognostics has a 12 month low of $2.79 and a 12 month high of $11.05.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million. During the same period in the previous year, the business posted ($0.25) earnings per share. Sell-side analysts anticipate that Sera Prognostics will post -0.96 earnings per share for the current year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.